Bydureon Helps Reduce A1C
Once-weekly exenatide (Bydureon) has been around only since 2012, but researchers found that it can stand up to the older diabetes medication insulin detemir (Levemir), which is taken once or twice daily. The study included people with type 2 diabetes taking metformin or metformin plus a sulfonylurea and not reaching their A1C goals (average A1C was 8.4 percent at the study's start). Participants who added once-weekly exenatide lowered their A1C an average of 1.3 percentage points over six months, while subjects who added insulin detemir experienced a 0.9-percentage-point reduction. Once-weekly exenatide was also associated with 6 pounds of weight loss on average, while the insulin users typically gained a couple of pounds. The study was partially supported by Amylin Pharmaceuticals, maker of Bydureon.
Source: Diabetes Care, published online Dec. 28, 2012